Latest Breaking News On - Fast track status - Page 9 : comparemela.com

Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasWalter klempMoleculin biotech incDrug administrationExchange commissionSecurities exchangeMoleculin biotechMoleculin chairmanPartial responseFast track statusOrphan drug designationTranscription modulatorSecurities actSecurities exchange actPrivate securities litigation reform act

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) - read this article along with other careers information, tips and advice on BioSpace

United statesJenene thomasGill shephardWalter klempLiposomal annamycinItalian national institute of healthMoleculin biotech incDrug administrationExchange commissionCompany codesSecurities exchangePrnewswire moleculin biotech incItalian medicines agencyAgenzia italiana del farmacoIstituto superioreItalian national institute

Moleculin Biotech (MBRX) Approved in Italy for Phase 1/2 Trial of Annamycin in Combination with Cytarabine

Moleculin Biotech (MBRX) Approved in Italy for Phase 1/2 Trial of Annamycin in Combination with Cytarabine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Walter klempItalian national institute of healthMoleculin biotech incDrug administrationItalian medicines agencyAgenzia italiana del farmacoIstituto superioreItalian national instituteFast track statusOrphan drug designation

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasGill shephardWalter klempLiposomal annamycinItalian national institute of healthMoleculin biotech incDrug administrationExchange commissionSecurities exchangePrnewswire moleculin biotech incItalian medicines agencyAgenzia italiana del farmacoIstituto superioreItalian national instituteFast track status

Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)

Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock Next generation anthracycline,.

United statesJenene thomasGill shephardWalter klempLiposomal annamycinCompany annamycinMoleculin biotech incExchange commissionAmerican society of hematologySecurities exchangeOrphan drugMoleculin biotechAmerican societyAnnual meetingPartial responseFast track status